Alvotech and Advanz Pharma have inked a deal to expand their commercial partnership to cover three additional biosimilar candidates.

The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate.

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free ...

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

Biologics are complex medications made from living organisms. Biosimilars are close copies in structure and function to an FDA-approved biologic. Learn more.

Explore how biosimilars are lowering cancer drug costs and reshaping treatment access for patients, providers, and healthcare systems worldwide.

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara.

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics.

Sandoz’s filgrastim biosimilar, Zarxio®, received the first U.S. approval in 2015, whereas nine filgrastim biosimilars have been approved in Europe dating back to multiple authorizations in 2008.

GLOBAL BIOSIMILAR UPDATES Celltrion Bolsters Biosimilars Market Position in Italy Celltrion’s ustekinumab biosimilar, STEQEYMA ®, has won its first bid within 2 months of its launch in January ...

Metastatic squamous cell carcinoma of the head and neck carries a poor prognosis, but does cetuximab offer clinical benefits beyond those of platinum-based therapies?